TRYNGOLZA (olezarsen) is a specialized medication designed for the management of familial chylomicronemia syndrome (FCS), a rare genetic disorder causing very high triglyceride levels in the blood. It works by inhibiting apolipoprotein C-III (APOC-III), a protein responsible for regulating triglyceride metabolism, thereby lowering triglyceride levels. Administered once a month via subcutaneous injection, TRYNGOLZA helps reduce the risk of complications like pancreatitis associated with FCS.

This drug is prescribed as an adjunct to a low-fat diet, offering patients with FCS a vital tool for managing their condition. As a highly targeted treatment, TRYNGOLZA is tailored to patients with this specific lipid metabolism disorder and represents an advancement in the therapeutic approach to hypertriglyceridemia. Regular monitoring and adherence to dosing instructions are essential for achieving optimal therapeutic outcomes.